Related Experiment Video
Updated: Apr 5, 2026
Zebra II as A Novel System to Record Electrophysiological Signals in Zebrafish
Published on: August 16, 2024
Recent progress in the use of zebrafish for novel cardiac drug discovery
Mirjam Keßler1, Wolfgang Rottbauer1, Steffen Just1
1a University of Ulm, Department of Medicine II , Albert-Einstein-Allee 23, 89081 Ulm, Germany +49 73 150 045 118 ; +49 73 150 045 159 ; steffen.just@uniklinik-ulm.de.
Insights
The zebrafish model offers a powerful in vivo system for cardiovascular disease research and drug discovery. Advanced techniques like CRISPR/Cas9 enable precise disease modeling for personalized medicine and efficient drug screening.
Area of Science:
- Cardiovascular research
- In vivo drug discovery
- Genetics and molecular biology
Background:
- Cardiovascular disease (CVD) is a major global health burden, driving significant healthcare costs.
- Human genetic and animal model studies are crucial for understanding CVD etiology and identifying therapeutic targets.
- The zebrafish has become a key in vivo model for studying human cardiovascular diseases and for drug discovery.
Purpose of the Study:
- To review the rationale for using zebrafish in whole-organism drug discovery.
- To highlight advancements in drug target identification, disease modeling, and high-throughput screening automation.
Main Methods:
- Review of current literature on zebrafish as an in vivo model.
- Discussion of genome-editing technologies (CRISPR/Cas9, TALEN) for disease modeling.
- Exploration of high-throughput small compound screening and systems biology approaches.
Main Results:
- Zebrafish provide a versatile platform for in vivo cardiovascular research.
- Genome editing facilitates accurate modeling of human cardiovascular diseases.
- Automation and systems biology enhance drug discovery efficiency.
Conclusions:
- Genome-editing tools like CRISPR/Cas9 and TALEN enable efficient in vivo disease modeling in zebrafish.
- Animal models simulating patient conditions, coupled with next-generation screening, advance personalized therapeutic options.
- Systems biology approaches are vital for target identification, in vivo disease modeling, and future drug discovery.
Introduction:
Cardiovascular disease is the leading cause of morbidity and mortality worldwide, thereby putting a large burden on our healthcare costs. Using both human genetic approaches, as well as forward and reverse genetic strategies in animal models, significant progress has been made to unravel the genetic and molecular etiology of human cardiovascular disease that is crucial to define novel therapeutic targets. In this context, the zebrafish has emerged as an important in vivo vertebrate animal system to study and to model human cardiovascular diseases as well as for in vivo cardiovascular drug discovery.
Areas Covered:
This review describes the rationale for using the in vivo model system zebrafish in whole-organism-based drug discovery strategies. It also highlights recent developments in the fields of drug target identification, disease modeling, and automation of high-throughput small compound screening.
Expert Opinion:
Novel genome-editing techniques such as the clustered regularly interspaced short palindromic repeat/Cas9 (CRISPR/Cas9) and transcription activator-like effector nuclease (TALEN) technologies allow highly efficient and reliable disease modeling in the in vivo system zebrafish. The ambition of developing personalized therapeutic options will clearly be fostered by the establishment of animal disease models that accurately simulate the patient's situation and the use of these disease models in 'next-generation' high-throughput small compound screens to define treatment options tailored to individual needs. To define suitable targets for therapeutic modulation, systems biology approaches that study complex biological systems as an integrated whole will pave the way to successful in vivo disease modeling and future drug discovery.
